- Home
- EWBC vs JAZZ Comparison
EWBC vs JAZZ Comparison
Compare EWBC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EWBC | JAZZ |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | 2890 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2B | 15.6B |
| IPO Year | 1998 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EWBC | JAZZ |
|---|---|---|
| Price | $127.77 | $248.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $131.14 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 1.0M | 805.3K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | 2.57 | ★ 4.43 |
| Revenue | $55,316,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $13.49 | $6.22 |
| Revenue Next Year | $5.78 | $7.68 |
| P/E Ratio | ★ $50.84 | $55.94 |
| Revenue Growth | ★ 3.12 | N/A |
| 52 Week Low | $92.67 | $105.00 |
| 52 Week High | $136.00 | $249.64 |
Technical Indicators
Market Signals| Indicator | EWBC | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 66.57 |
| Support Level | $125.18 | $222.49 |
| Resistance Level | $136.00 | N/A |
| Average True Range (ATR) | 3.01 | 6.75 |
| MACD | -0.40 | 1.55 |
| Stochastic Oscillator | 28.20 | 93.01 |
Price Performance
Historical ComparisonAbout EWBC East West Bancorp Inc.
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.